SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-124304
Filing Date
2021-10-07
Accepted
2021-10-07 21:10:10
Documents
2
Period of Report
2021-10-01

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2129004-6_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2129004-6_3seq1.xml 3 1629
2 EXHIBIT 24.1 tm2129004d6_ex24-1.htm EX-24.1 8630
  Complete submission text file 0001104659-21-124304.txt   11775
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Issuer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NABRIVA THERAPEUTICS PLC 414 COMMERCE DRIVE, SUITE 120 FORT WASHINGTON PA 19034
Business Address
Guico-Pabia Christine J. (Reporting) CIK: 0001887144 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37558 | Film No.: 211313680